Tenofovir alafenamid prophylaxis for the prevention of HBV reactivation in immunosuppressed subjects: a multicenter study
Articles > Article · 2022
Authors: ŞEBNEM ŞENOL AKAR, Ufuk Sonmez, TUNA DEMİRDAL, Pinar Sen, Deniz Ozer, Sabri Atalay, Deniz AKYOL, Cigdem Mermutluoglu, MUSTAFA KEMAL ÇELEN, Tansu YAMAZHAN, Hüsnü PULLUKÇU
CUKUROVA MEDICAL JOURNAL, Journal Indexed in SCI Expanded, International, 2022, vol 47, pp 446-454
Summary
Purpose: Reactivation of hepatitis B may be prevented by antiviral therapy in immunosuppressed high risk patients. Entecavir (ETC) and tenofovir disoproksil fumarat (TDF) have been used for a long time and recently introduced tenofovir alafenamid (TAF) seems to be a good alternative with rare side effects. This multicentered study with a large patient population aimed to investigate the effectiveness of tenofovir alafenamid (TAF) in immunsuppressed subjects.